Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib (JACKPOT8) Sunvozertinib achieved an ORR of 60.8% in ≥ second-line treatment and 77.8% in the first-line treatment for EGFR…